{
    "clinical_study": {
        "@rank": "13386", 
        "acronym": "LIFE-HIV", 
        "arm_group": [
            {
                "arm_group_label": "Treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Losartan 100mg daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the potential effectiveness of losartan (100mg\n      daily) for reducing inflammation and improving immune recovery."
        }, 
        "brief_title": "Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial", 
        "condition": [
            "Inflammation", 
            "Fibrosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Inflammation"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV infection (verified by previous positive antibody or detectable HIV RNA level)\n\n          -  Age > 50 years\n\n          -  Receiving continuous ART for >= 2 years (regimen changes > 6 months prior to\n                enrollment are allowed)\n\n          -  HIV RNA level < 200 copies/mL for >= 1 year (1 measure >= 200 allowed if also < 1000\n             and preceded and followed by values < 200 copies/mL)\n\n          -  Blood CD4+ T-cell count < 600 cells/mm cubed\n\n          -  Systolic blood pressure > 120 mmHg (mean value if >= 2 measures obtained)\n\n          -  Estimated glomerular filtration rate (GFR )> 30 mL/min/1.73 m squared\n\n          -  Do not anticipate starting or stopping statin or aspirin therapy during the study\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breastfeeding\n\n          -  A contra-indication to taking an angiotensin receptor blocker (ARB) (e.g., cirrhosis,\n             prior angioedema with angiotensin-converting enzyme inhibitor (ACE-I), or use of drug\n             with potential drug-interaction [e.g., rifaximin])\n\n          -  A clinical indication for ARB or ACE-I therapy (e.g., cardiovascular disease (CVD),\n             stroke, or diabetes mellitus (DM))\n\n          -  Current treatment with ARB or medication with overlapping mechanism (e.g., ACE-I or\n             aldosterone antagonist)\n\n          -  Current treatment with immunomodulatory drugs within the past 6 months\n\n          -  Current hepatitis treatments (e.g., interferon, ribavirin) within the past 6 months\n\n          -  Serum potassium > 5.0 millimoles per liter (mmol/L) within 3 months of entry\n\n          -  Invasive cancer in the prior year or receiving cancer treatment (not including\n             carcinoma-in-situ or basal cell cancer of the skin)\n\n          -  Cirrhosis or end-stage liver disease\n\n          -  Rheumatologic or chronic inflammatory disease (e.g., systematic lupus erythematous,\n             psoriasis, rheumatoid arthritis, vasculitis, sarcoidosis, Crohn's disease)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02049307", 
            "org_study_id": "PCC-007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "Losartan 100mg daily", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Matching placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Losartan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 24, 2014", 
        "number_of_arms": "2", 
        "official_title": "Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial", 
        "overall_contact": {
            "email": "baker@umn.edu", 
            "last_name": "Jason Baker, M.D.", 
            "phone": "612-873-2700"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in plasma IL-6 levels from baseline over 12 months", 
            "measure": "Interleukin 6 (IL-6) plasma levels", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02049307"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Minneapolis Medical Research Foundation", 
            "investigator_full_name": "Jason Baker", 
            "investigator_title": "Protocol Chair", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Change in CD4+ cell count from baseline over 12 months", 
            "measure": "Cluster of differentiation 4 (CD4+) cell count", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Minneapolis Medical Research Foundation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Minneapolis Medical Research Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}